07:01 AM EDT, 06/02/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that DATROWAY, a TROP2-directed antibody drug conjugate, showed promising efficacy and safety in early and advanced non-small cell lung cancer across multiple trials.

In the TROPION-Lung02 trial, 96 patients received DATROWAY with pembrolizumab, with or without platinum chemo, showing response rates over 54% and disease control rates above 88%, the company said.

The TROPION-Lung04 study involved 40 patients treated with DATROWAY and rilvegostomig, delivering a 57.5% response rate and 95% disease control rate across PD-L1 levels and histologies, Astrazeneca ( AZN ) said.

The company said NeoCOAST-2 enrolled 63 patients who received DATROWAY with durvalumab and chemo before surgery, resulting in a 35.2% pathologic complete response rate and 63% major pathologic response rate.

All combination regimens showed safety profiles in line with known effects of the respective therapies, and no new safety concerns were identified, the company added.

Further evaluations are ongoing through the TROPION clinical program, including phase 3 trials, to assess DATROWAY's potential across treatment settings, Astrazeneca ( AZN ) said.